Jin Yang-gon, HLB Chairman, Buys Additional 160,000 HLB Innovation Shares

"Reflecting Commitment to Responsible Management and Enhanced Shareholder Value"

Jin Yang-gon, Chairman of HLB Group, has reaffirmed his commitment to responsible management by purchasing HLB Innovation shares on the open market.

On February 3, HLB Innovation announced in a public filing that Chairman Jin acquired 160,000 HLB Innovation shares through open-market purchases. As a result, his total holdings increased to 702,407 shares.

Starting with his first open-market purchase in January last year, Chairman Jin bought a total of 542,407 shares over 12 separate transactions through the end of last year.

HLB Innovation expects its corporate value to rise as the clinical achievements of its U.S. subsidiary, Verismo Therapeutics, which is based on the KIR-CAR platform, become more tangible. Verismo's CAR-T pipeline is a second-generation technology that improves on the "T-cell exhaustion" issue that has been cited as a limitation of existing therapies.

The company plans to release interim Phase 1 clinical results for its solid-tumor CAR-T therapy "SynKIR-110" in the first half of this year. It also plans to present interim results for its hematologic-cancer CAR-T therapy "SynKIR-310" at a global conference.

An HLB Innovation official said, "As Verismo Therapeutics' clinical achievements are released step by step, this year will mark the beginning of a full-fledged revaluation of our corporate value," adding, "We will steadfastly execute our mid- to long-term growth strategy without wavering."

This content was produced with the assistance of AI translation services.